Latest Quidel Corp (QDEL) Headlines Commit To B
Post# of 38
Posted On: 03/13/2014 1:04:25 PM
Latest Quidel Corp (QDEL) Headlines
Commit To Buy Quidel Corp. At $22.50, Earn 6.8% Annualized Using Options
at The Street - Wed Mar 12, 10:53AM CDT
Investors considering a purchase of Quidel Corp. stock, but tentative about paying the going market price of $28.57/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Quidel to Present at Cowen 34th Annual Health Care Conference
Marketwire - Tue Feb 18, 4:30PM CST
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Cowen and Company 34th Annual Health Care Conference to be held at the Boston Marriott Copley Place hotel in Boston, Massachusetts on Monday, March 3, 2014.
Quidel Reports Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Tue Feb 11, 3:10PM CST
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and full year ended December 31, 2013.
CareFusion Up on Terumo Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 4:45PM CST
CareFusion announced an eight-year agreement with Terumo
Quidel Shares Up 15.9% Since SmarTrend's Buy Recommendation (QDEL)
Comtex SmarTrend(R) - Fri Jan 31, 9:22AM CST
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on December 16th, 2013 at $25.95. In approximately 2 months, Quidel has returned 15.86% as of today's recent price of $30.06.
Covidien Unveils New Training Center - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 5:10PM CST
Covidien expands business in emerging markets and opens a training and education center in India.
Quidel to Hold Fourth Quarter and Full Year 2013 Financial Results Conference Call on February 11, 2014
Marketwire - Tue Jan 28, 3:30PM CST
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will release fourth quarter and full year 2013 financial results after market close on Tuesday, February 11, 2014.
Using the Short Ratio to Forecast Turning Points - Screen of the Week
Kevin Matras - ZACKS - Tue Jan 28, 2:04AM CST
Using the Short Ratio to Forecast Turning Points - Screen of the Week
Uptrend Call Working As Quidel Stock Rises 21.4% (QDEL)
Comtex SmarTrend(R) - Thu Jan 23, 5:10PM CST
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on December 16th, 2013 at $25.95. In approximately 1 month, Quidel has returned 21.37% as of today's recent price of $31.49.
Stryker Beats Q4 Earnings, Initiates Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 10:30AM CST
Stryker Corporation reported adjusted EPS of $1.23 in the fourth quarter of 2013, up 7.9% year over year.
Quidel Up 22.0% Since SmarTrend Uptrend Call (QDEL)
Comtex SmarTrend(R) - Thu Jan 16, 11:15AM CST
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on December 16th, 2013 at $25.95. In approximately 1 month, Quidel has returned 22.03% as of today's recent price of $31.66.
Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics
PR Newswire - Tue Jan 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
18.1% Return Seen to Date on SmarTrend Quidel Call (QDEL)
Comtex SmarTrend(R) - Thu Jan 09, 10:03AM CST
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on December 16th, 2013 at $25.95. In approximately 3 weeks, Quidel has returned 18.10% as of today's recent price of $30.64.
Quidel Corporation reports preliminary Q4 2013 revenue of USD50m
M2 - Thu Jan 09, 5:51AM CST
Diagnostic testing solutions company Quidel Corporation (NASDAQ:QDEL) revealed on Wednesday that its Q4 2013 revenue is expected to be approximately USD50m.
Quidel Announces Preliminary Revenue for Fourth Quarter 2013
Marketwire - Wed Jan 08, 3:15PM CST
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the fourth quarter of 2013 to be approximately $50 million.
Stock Movements, FDA Clearances, Collaborations, and Agreements - Research Report on CytRx, Quidel, Repligen, Intrexon, and Acacia
PR Newswire - Mon Jan 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting CytRx Corporation (NASDAQ: CYTR), Quidel Corp. (NASDAQ: QDEL), Repligen Corporation (NASDAQ: RGEN), Intrexon Corporation (NYSE: XON), and Acacia Research Corporation (NASDAQ: ACTG). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Quidel Corporation (QDEL): Moving Average Crossover Spotted - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 7:54AM CST
Quidel Corporation (QDEL): Moving Average Crossover Spotted
Good News for Quidel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 3:35PM CST
Quidel Corp. received encouraging news when the FDA cleared 510(k) for the sale of its AmpliVue Group B Strep Assay.
Commit To Buy Quidel Corp. At $22.50, Earn 6.8% Annualized Using Options
at The Street - Wed Mar 12, 10:53AM CDT
Investors considering a purchase of Quidel Corp. stock, but tentative about paying the going market price of $28.57/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Quidel to Present at Cowen 34th Annual Health Care Conference
Marketwire - Tue Feb 18, 4:30PM CST
Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Cowen and Company 34th Annual Health Care Conference to be held at the Boston Marriott Copley Place hotel in Boston, Massachusetts on Monday, March 3, 2014.
Quidel Reports Fourth Quarter and Full Year 2013 Financial Results
Marketwire - Tue Feb 11, 3:10PM CST
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and full year ended December 31, 2013.
CareFusion Up on Terumo Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 4:45PM CST
CareFusion announced an eight-year agreement with Terumo
Quidel Shares Up 15.9% Since SmarTrend's Buy Recommendation (QDEL)
Comtex SmarTrend(R) - Fri Jan 31, 9:22AM CST
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on December 16th, 2013 at $25.95. In approximately 2 months, Quidel has returned 15.86% as of today's recent price of $30.06.
Covidien Unveils New Training Center - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 5:10PM CST
Covidien expands business in emerging markets and opens a training and education center in India.
Quidel to Hold Fourth Quarter and Full Year 2013 Financial Results Conference Call on February 11, 2014
Marketwire - Tue Jan 28, 3:30PM CST
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will release fourth quarter and full year 2013 financial results after market close on Tuesday, February 11, 2014.
Using the Short Ratio to Forecast Turning Points - Screen of the Week
Kevin Matras - ZACKS - Tue Jan 28, 2:04AM CST
Using the Short Ratio to Forecast Turning Points - Screen of the Week
Uptrend Call Working As Quidel Stock Rises 21.4% (QDEL)
Comtex SmarTrend(R) - Thu Jan 23, 5:10PM CST
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on December 16th, 2013 at $25.95. In approximately 1 month, Quidel has returned 21.37% as of today's recent price of $31.49.
Stryker Beats Q4 Earnings, Initiates Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 10:30AM CST
Stryker Corporation reported adjusted EPS of $1.23 in the fourth quarter of 2013, up 7.9% year over year.
Quidel Up 22.0% Since SmarTrend Uptrend Call (QDEL)
Comtex SmarTrend(R) - Thu Jan 16, 11:15AM CST
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on December 16th, 2013 at $25.95. In approximately 1 month, Quidel has returned 22.03% as of today's recent price of $31.66.
Conferences, Preliminary Revenues, Board Changes, Shareholders' Meeting Results, and Clinical Trial Initiation - Research Report on Antares, Quidel, bluebird bio, Given Imaging, and Immunomedics
PR Newswire - Tue Jan 14, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Antares Pharma, Inc. (NASDAQ: ATRS), Quidel Corporation (NASDAQ: QDEL), bluebird bio, Inc. (NASDAQ: BLUE), Given Imaging Ltd. (NASDAQ: GIVN), and Immunomedics, Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
18.1% Return Seen to Date on SmarTrend Quidel Call (QDEL)
Comtex SmarTrend(R) - Thu Jan 09, 10:03AM CST
SmarTrend identified an Uptrend for Quidel (NASDAQ:QDEL) on December 16th, 2013 at $25.95. In approximately 3 weeks, Quidel has returned 18.10% as of today's recent price of $30.64.
Quidel Corporation reports preliminary Q4 2013 revenue of USD50m
M2 - Thu Jan 09, 5:51AM CST
Diagnostic testing solutions company Quidel Corporation (NASDAQ:QDEL) revealed on Wednesday that its Q4 2013 revenue is expected to be approximately USD50m.
Quidel Announces Preliminary Revenue for Fourth Quarter 2013
Marketwire - Wed Jan 08, 3:15PM CST
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the fourth quarter of 2013 to be approximately $50 million.
Stock Movements, FDA Clearances, Collaborations, and Agreements - Research Report on CytRx, Quidel, Repligen, Intrexon, and Acacia
PR Newswire - Mon Jan 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting CytRx Corporation (NASDAQ: CYTR), Quidel Corp. (NASDAQ: QDEL), Repligen Corporation (NASDAQ: RGEN), Intrexon Corporation (NYSE: XON), and Acacia Research Corporation (NASDAQ: ACTG). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Quidel Corporation (QDEL): Moving Average Crossover Spotted - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 7:54AM CST
Quidel Corporation (QDEL): Moving Average Crossover Spotted
Good News for Quidel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 3:35PM CST
Quidel Corp. received encouraging news when the FDA cleared 510(k) for the sale of its AmpliVue Group B Strep Assay.
(0)
(0)Quidel Corp. (QDEL) Stock Research Links
Scroll down for more posts ▼